Pipeline

Our Pipeline – Advancing Next-Generation Immunotherapies

At Plectonic Biotech, we are developing a groundbreaking DNA-based immunotherapy platform designed to overcome the limitations of conventional antibody and cell therapies. Our LOGIBODY technology introduces a novel logic-gated mechanism that enables precise tumor targeting while reducing off-target effects—bringing a new level of control and specificity to cancer treatment.

Pipeline Overview

We are currently in the preclinical development stage, focusing on two distinct oncology indications (currently undisclosed). Our research aims to validate the safety, efficacy, and scalability of LOGIBODY-based therapeutics, paving the way for clinical translation.

Plectonic Biotech – Overview for the LOGIBODY pipeline

Key Focus Areas

  • Preclinical validation to establish proof-of-concept and optimize therapeutic design
  • Scalable manufacturing to ensure clinical and commercial feasibility
  • Strategic collaborations with academic institutions, biotech, and pharma partners to accelerate clinical development

Partnerships & Collaborations

To bring LOGIBODY to patients, we are actively seeking pharmaceutical and biotech partnerships for clinical development, manufacturing, and commercialization. Our goal is to jointly advance LOGIBODY into clinical trials and ultimately deliver best-in-class immunotherapies to improve patient outcomes.

Stay tuned as we progress toward the next milestone—bringing LOGIBODY into the clinic and transforming cancer treatment.